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Bicuspid aortic valve (BAV) stenosis has been considered a contraindication to transcatheter
aortic valve implantation (TAVI). The aim of this study is to compare the efficacy and safety
of TAVI in patients with BAV with those with tricuspid aortic valve (TAV) using balloon-
expandable and self-expanding transcatheter heart valves. This retrospective study included
823 consecutive patients with severe, symptomatic aortic valve stenosis undergoing TAVI
in 2 institutions, Baylor Heart and Vascular Hospital (Dallas, TX) and The Heart Hospi-
tal Baylor Plano (Plano, TX), from January 2012 to February 2016. Efficacy was evaluated
by postprocedural valve function as mean gradient, peak velocity, effective orifice area, and
≥moderate paravalvular leak. Safety end points included all-cause 30-day and 1-year mor-
tality, immediate postprocedural mortality and 30-day cardiovascular mortality, procedural
success, pacemaker implantation, and procedural complications. Of the 823 included pa-
tients, 735 had TAV and 77 had BAV. Baseline characteristics were similar between the 2
groups. Procedural success was high in both BAV and TAV (98.7% vs 99.1%, p = ns). There
were no significant differences between groups in valve hemodynamics after TAVI, pace-
maker implantation rate, or procedural complications. There were no differences regarding
immediate postprocedural mortality (BAV vs TAV, 1.1% vs 0.8%, p = ns), nor 30-day car-
diovascular mortality (3.4% vs 2.3%, p = ns). All-cause mortality at 30 days (3.4% vs 3.1%,
p = ns) and 1-year (8.5% vs 10.5%) were similar. Patients with BAV showed similar pro-
cedural and clinical outcomes to patients with TAV. Therefore, TAVI appears to be a safe
and effective procedure for patients with BAVs as well as those with TAVs. © 2017 Elsevier
Inc. All rights reserved. (Am J Cardiol 2017;■■:■■–■■)
Bicuspid aortic valve (BAV) is one of the most common
congenital heart disorders, occurring in 1% to 2% of the
general population, with a male preponderance ratio of 2:1.1,2
It occurs either in isolation or in association with complex
congenital heart defects. BAV is associated with increased
mechanical stress, which predisposes to calcification and de-
velopment of aortic stenosis (AS) and/or aortic regurgitation.3
Aortopathy may accompany BAV, leading to ascending aortic
enlargement, aneurysm formation, and aortic dissection.4
Transcatheter aortic valve implantation (TAVI) is currently
approved for the treatment of intermediate- to high-risk pa-
tients with severe AS. Despite previous assumptions, BAV
is common even in octogenarians with symptomatic AS.5
However, BAV has been considered a relative contraindica-
tion to TAVI. Therefore, data on the role of TAVI in the
treatment of severe AS in patients with BAV are limited
because such patients were excluded from most clinical trials
because of concerns regarding uneven valve expansion, bio-
prosthesis malposition or malfunction, paravalvular leak,
annular rupture, or aortic dissection.6 However, case reports
and small case series have suggested that TAVI can be suc-
cessfully performed with acceptable clinical outcomes in high-
risk patients with BAV.7–10 Some reports have suggested higher
success rate with new-generation devices than earlier
devices.11,12 Recently, results from a multicenter registry re-
ported a higher procedural complication rate and incidence
of paravalvular leak in patients with BAV.13 In light of this
discordant evidence, we report the efficacy and safety of TAVI
in a large series of patients with BAV in comparison with pa-
tients with tricuspid aortic valve (TAV).
Methods
Data were collected on consecutive patients with severe,
symptomatic AS undergoing TAVI at Baylor Heart and Vas-
cular Hospital (Dallas, TX) and The Heart Hospital Baylor
Plano (Plano, TX) from January 2012 to February 2016. Base-
line demographics, procedural data, and clinical outcomes were
retrospectively collected and analyzed. For the purpose of the
current analysis, data from both medical centers were pooled,
and a joint database was created. The study was approved by
the Baylor Institutional Review Board.
Patients were stratified into 2 groups according to
aortic valve morphology as detected at intra-procedural
transesophageal echocardiography and preprocedural com-
puted tomography (CT) scans. BAV morphology was classified
as previously described by Sievers and Schmidtke14 according
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to the number of cusps and the presence of raphes, as well as
spatial position and symmetry of raphes and cusps: (1) type
0 in the presence of 2 symmetric leaflets or cusps and 1 com-
missure without evidence of a raphe; (2) type 1, presence of
1 raphe; (3) and type 2, presence of 2 raphes. The imaging
studies were reviewed by 2 experts (PAG and AS). Patients
were excluded if the diagnosis of BAV was not consistent or
remained uncertain after both transesophageal echocardiography
and CT evaluation. Follow-up was obtained by clinical visits
and clinical charts revision.
Primary efficacy end points included measures of pros-
thetic valve function, defined according to the Valve Academic
Research Consortium criteria as mean gradient, peak veloc-
ity, effective orifice area, and ≥moderate paravalvular leak.15
Safety end points included all-cause 30-day and 1-year mor-
tality, immediate postprocedural mortality and 30-day
cardiovascular mortality, pacemaker implantation, and the in-
cidence of procedural complications (acute kidney injury,
vascular complication, minor, major, and life-threatening
bleedings, stroke or transient ischemic attack, valve-in-
valve intervention, procedural success), defined in accordance
to the Valve Academic Research Consortium criteria.15 Pro-
cedural success was defined as deployment of the valve as
intended, without need for conversion to immediate surgery.
The degree of postprocedural PVL was evaluated by both an-
giography and transesophageal echocardiography at the end
of the TAVI procedure after final device deployment.
Continuous variables are summarized as mean ± stan-
dard deviation (SD) or as medians and interquartile range as
appropriate, and were compared using Student t test or Mann-
Whitney rank sum test. Categorical variables were compared
using chi-square or the Fisher’s exact test. Survival curves
were constructed using Kaplan-Meier estimates, whereas com-
parisons relied on the log-rank test. A 2-sided alpha level of
0.05 was used for all superiority testing. All statistical analy-
ses were performed using SPSS Statistics version 19 (SPSS
Inc., Chicago, IL).16,17
Results
Between January 2012 and February 2016, 829 patients
underwent TAVI in the included institutions. Of those, 88 were
classified as BAV, 735 as TAV, and 6 were excluded because
valve morphology could not be clearly established. Base-
line characteristics are summarized in Table 1. Patients with
BAV displayed a higher prevalence of peripheral arterial
disease (70.9% vs 67.1%, p = 0.033); moreover, the BAV group
had a slightly smaller calculated aortic valve area at base-
line (0.65 ± 0.17 vs 0.69 ± 0.19, p = 0.049). The 2 groups were
otherwise similar in baseline characteristics, as well as base-
line echocardiographic features. The most common
morphology in BAVs was type 1 (85.2%), followed by type
0 (13.6%) and type 2 (1.1%). No differences emerged in the
type valve and approach used. Of the total study popula-
tion, 616 were treated with older devices (Sapien-XT: n = 384,
CoreValve: n = 232), and 204 were treated with newer gen-
eration devices (Sapien 3: n = 99, Evolut: n = 83, Lotus:
n = 22). One-year follow-up was completed by 92% of the
initial population.
Postprocedural echocardiographic findings are described
in Table 2. After TAVI, both patients with BAV and patients
with TAV had similar values for mean aortic gradient
(7.96 ± 4.15 vs 8.5 ± 4.2, p = 0.268, Figure 1) and peak aortic
velocity (1.9 ± 0.4 vs 2.02 ± 0.51, p = 0.265). Postprocedural
aortic valve area was slightly larger in the BAV group than
in the TAV group (2.15 ± 0.55 vs 1.90 ± 0.54, p = 0.007).
The incidence of ≥moderate PVL was low in our popula-
tion, with no differences in patients with BAV or TAV (5.3%
vs 5.0%, p = 0.903, respectively; Figure 2). Table 3 de-
scribes procedural and follow-up clinical outcomes of the study
population. Patients with BAV and those with TAV showed
similar incidence of acute kidney injury (3.4% vs 2.3%,
p = 0.528), vascular complications (4.5% vs 4.8%, p = 0.928),
life-threatening, major, and minor bleeding (0.4% vs 0%,
p = 0.792; 3.4% vs 2.0%, p = 0.792 and 9.1% vs 9.1%,
p = 792), stroke (2.3% vs 3.7%, p = 0.499), and valve-in-
valve intervention (3.4% vs 1.6%, p = 0.240). Procedural
success was high in the whole population and not different
between the 2 groups (98.7% vs 99.1%, p = ns). Rate of pace-
maker implantation was similar between the 2 groups (22.7%
vs 18.2%, p = 0.303). Similarly, immediate postprocedural mor-
tality (1.1% vs 0.8%, p = 0.757), 30-day cardiovascular (3.4%
vs 2.3%, p = 0.528) and all-cause mortality (3.4% vs 3.1%,
p = 0.887), as well as 1-year all-cause mortality (8.5% vs
10.5%, p = 0.579) did not differ between groups. Even after
stratifying the population according to newer versus older gen-
eration device, no differences in 1-year mortality were observed
(Figure 3).
Discussion
In this large patient cohort, no significant differences were
found in clinical outcomes of patients undergoing TAVI with
BAV. Although the use of TAVI in patients with BAV is in-
creasing, TAVI is not currently approved for use in patients
with BAV in the United States. The reasons for this lie in theo-
retical concerns regarding the elliptical shape of leaflet opening
in BAV together with a possible asymmetric distribution of
calcification. Accordingly, patients with known BAV have been
excluded from TAVI clinical trials, or are younger patients
with low surgical risk for whom TAVI is not currently ap-
proved. As a result, the available evidence regarding TAVI
in BAV (Table 4) comes mostly from case reports or small
series and few registries.7–10,13,18 One large registry has been
recently published on this topic, showing overall good result
of TAVI in patients with BAV especially with newer genera-
tion devices.11 However, the majority of the studies have been
performed with first-generation transcatheter heart valve
(THV). In our population, BAV and TAV showed similar he-
modynamic results after TAVI. Moreover, the incidence of
significant paravalvular leak was not different between groups.
Previous reports have shown conflicting evidence regarding
the risk of significant paravalvular leak in patients with BAV
compared with those with TAV.7–9 The German TAVI Reg-
istry described a higher frequency of residual paravalvular
leak in patients with BAV.7 A recent report from the Bicus-
pid TAVI Registry, including 301 patients with BAV, reported
a significantly lower rate of paravalvular leak in patients being
treated with new-generation (Sapien 3 and Lotus) com-
pared with first-generation THV (Sapien XT and CoreValve).11
The findings were recently confirmed a propensity matched
comparison of patients with BAV and those with TAV.13
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Table 1
Characteristics of the study population
Aortic Valve Structure
Variables Bicuspid
(n = 88)
Tricuspid
(n = 735)
p value
Baseline characteristics
Age, mean ± SD (years) 80.2 ± 8.4 81.8 ± 7.9 0.081
Men 53 (60.2%) 389 (52.9%) 0.194
Body Mass Index, mean ± SD (kg/m2) 27.0 ± 6.8 27.6 ± 6.6 NS
Society of Thoracic Surgery risk of mortality, mean ± SD 7.4 ± 3.9% 7.6 ± 3.9% NS
Hypertension 71 (81.6%) 612 (84.3%) 0.518
Hyperlipidemia 62 (72.1%) 516 (71.7%) 0.934
Diabetes mellitus 29 (37.7%) 283 (40.4%) 0.645
Chronic kidney disease 45 (52.3%) 330 (45.5%) 0.227
End stage renal disease 4 (5.3%) 21 (3.1%) 0.315
Coronary artery disease 61 (70.9%) 487 (67.1%) 0.471
Peripheral arterial disease 35 (43.2%) 219 (31.5%) 0.033
Chronic obstructive pulmonary disease 15 (19.5%) 149 (22.1%) 0.602
Atrial Fibrillation 15 (17.9%) 142 (19.6%) 0.789
Previous bypass surgery/percutaneous coronary intervention 40 (49.4%) 322 (46.1%) 0.571
Previous stroke 17 (22.4%) 132 (19.5%) 0.556
Echocardiographic findings
Left ventricle ejection fraction <50% 28 (31.8%) 197 (27.1%) 0.354
Aortic valve mean gradient, mean ± SD (mmHg) 46.9 ± 16.9 44.3 ± 13.6 0.102
Aortic valve area, mean ± SD (cm2) 0.65 ± 0.17 0.69 ± 0.19 0.049
Aortic regurgitation ≥moderate 8 (9.1%) 76 (10.4%) 0.700
Mitral regurgitation ≥moderate 14 (15.9%) 140 (19.1%) 0.472
Mitral annular calcium ≥moderate 55 (62.5%) 388 (53.1%) 0.094
Pulmonary Hypertension 49 (71.0%) 410 (75.6%) 0.402
Bicuspid Morphology Type
0 12 (13.6%)
1 75 (85.2%)
2 1 (1.1%)
Procedural characteristics
Type of Valve 0.174
Balloon-expandable 46 (52.3%) 439 (59.8%)
1st generation 36 (40.9%) 348 (47.3%)
new generation 10 (11.4%) 89 (12.1%)
Self-expandable 42 (47.7%) 295 (40.2%)
1st generation 30 (34.1%) 202 (27.5%)
new generation 12 (13.6%) 93 (12.6%)
Approach 0.622
Trans-femoral 640 (89.1%)
Trans-apical 8 (9.1%) 61 (8.3%)
Trans-aortic 1 (1.1%) 28 (3.8%)
Subclavian 1 (1.1%) 6 (0.8%)
Valve Size (mm)
Balloon-expandable 0.556
20 1 (2.2%) 4 (0.9%)
21 - 1 (0.2%)
23 11 (24.4%) 94 (22.0%)
25 - 5 (1.2%)
26 12 (34.5%) 159 (46.2%)
27 - 7 (1.6%)
29 18 (40.0%) 118 (27.6%)
31 3 (6.7%) 40 (9.3%)
Self-Expandable 0.500
20 1 (2.4%) 3 (1.0%)
23 7 (16.7%) 62 (21.4%)
25 - 5 (1.7%)
26 16 (38.1%) 95 (32.8%)
27 - 3 (1.0%)
29 17 (40.5%) 94 (32.4%)
31 1 (2.4%) 28 (9.7%)
SD = standard deviation.
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BAV was found in 10.7% of all patients undergoing TAVI
in this series. This may partly reflect selection bias in that
younger patients with known BAV tend to undergo surgical
aortic valve replacement in our institution. Many of the pa-
tients in this study were not known to have BAV preoperatively,
but were discovered during TAVI by transesophageal
echocardiography. As more and more patients are undergo-
ing TAVI using moderate sedation without transesophageal
echocardiography, it is likely that BAV will not be recog-
nized in many patients with calcified aortic valves. The ability
of transthoracic echocardiography to accurately classify aortic
valve morphology is only around 70%.19 Three-dimensional
transesophageal echocardiogram and 4-dimensional CT allow
superior detection of the number of commissures and raphes,
thus allowing classification of BAV versus TAV more
Table 2
Efficacy end points
Aortic Valve Structure
Bicuspid
(n = 88)
Tricuspid
(n = 735)
p value
Prosthetic Valve function
Mean Gradient (mmHg) 7.96 ± 4.15 8.5 ± 4.2 0.268
Peak Velocity, mean ± SD (m/s) 1.9 ± 0.40 2.02 ± 0.0.51 0.265
Effective Orifice Area,
mean ± SD (cm2)
2.15 ± 0.55 1.90 ± 0.54 0.007
Paravalvular leak ≥ moderate 4/75 (5.3%) 32/639 (5.0%) 0.903
LVEF = left ventricle ejection fraction.
Figure 1. Aortic mean gradient over time. Evolution of mean aortic gradi-
ent in patients with BAV and those with TAV at baseline and at different
time points after TAVI. BAV = bicuspid aortic valve; TAV = tricuspid aortic
valve; TAVI = transcatheter aortic valve implantation.
Figure 2. Paravalvular leak (PVL). Incidence of PVL over time in patients with BAV and those with TAV. BAV = bicuspid aortic valve; TAV = tricuspid
aortic valve.
Table 3
Safety end points
Aortic Valve Structure
Bicuspid
(n = 88)
Tricuspid
(n = 735)
p value
Acute Kidney Injury 3 (3.4%) 17 (2.3%) 0.528
Vascular complication 4 (4.5%) 35 (4.8%) 0.928
Minor Bleeding 8 (9.1%) 67 (9.1%) 0.792
Major Bleeding 3 (3.4%) 15 (2.0%) 0.792
Life-threatening bleeding - 3 (0.4%) 0.792
Stroke 2 (2.3%) 27 (3.7%) 0.499
Valve-in-Valve 3 (3.4%) 12 (1.6%) 0.240
Procedural success 76 (98.7%) 646 (99.1%) 0.556
Pacemaker Implantation 20 (22.7%) 133 (18.2%) 0.303
Immediate post-procedural
Mortality
1 (1.1%) 6 (0.8%) 0.757
30-day Cardiovascular Mortality 3 (3.4%) 17 (2.3%) 0.528
30-day All-cause Mortality 3 (3.4%) 23 (3.1%) 0.887
1-year All-cause Mortality 7 (8.5%) 68 (10.5%) 0.579
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precisely.20 It also helps avoid the common mistake of clas-
sifying patients as “functionally bicuspid” when a raphe is
mistaken for fusion of 2 of 3 leaflet edges.
Our study suffers from the known limitation intrinsic to
retrospective, observational study design. Although the de-
cision to refer a patient to TAVI or surgery was not randomized,
it was made by a Heart Valve Team with patients in the same
setting by a group of experienced cardiologists and heart sur-
geons. A prospective randomized trial of TAVI versus surgical
aortic valve replacement in patients with BAV is needed to
confirm that TAVI is an effective treatment for BAV.
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